An open-label, uncontrolled, prospective study of the effects of atorvastatin 10 mg on low-density lipoprotein cholesterol levels in chinese adults with coronary artery disease and hypercholesterolemia
| Autor: | Kin-Ming Tam, Albert Wai-Suen Leung, Chi-Suen Chiu |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Pharmacology
Chemotherapy medicine.medical_specialty business.industry medicine.medical_treatment Atorvastatin medicine.disease Gastroenterology Clinical trial Coronary artery disease Endocrinology Internal medicine Toxicity medicine lipids (amino acids peptides and proteins) Pharmacology (medical) Risk factor Prospective cohort study business Body mass index medicine.drug |
| Zdroj: | Current Therapeutic Research. 63:399-408 |
| ISSN: | 0011-393X |
| DOI: | 10.1016/s0011-393x(02)80044-3 |
| Popis: | Background: A high level of low-density lipoprotein cholesterol (LDL-C) is a major risk factor for coronary artery disease (CAD). Evidence shows that lowering LDL-C improves the outcomes of patients with CAD. Atorvastatin is an established drug for the treatment of hypercholesterolemia. Objective: The purpose of this open-label, uncontrolled, prospective study was to assess the effectiveness of treatment with atorvastatin 10 mg/d for 18 weeks in achieving the target level of LDL-C ( Methods: Chinese patients with CAD, hypercholesterolemia (defined as a baseline LDL-C level between 3.4 and 5.2 mmol/L [131–201 mg/dL]), and body mass index 2 were eligible. Atorvastatin 10 mg/d was given to each patient for 18 weeks. Lipid profiles were checked at 6, 12, and 18 weeks. To assess the extent of the achievement of NCEP LDL-C target levels, patients were categorized into 3 groups retrospectively according to baseline LDL-C level: group 1, 3.4 to 4.0 mmol/L (131–154 mg/dL); group 2, 4.01 to 4.6 mmol/L (155–178 mg/dL); and group 3, 4.61 to 5.2 mmol/L (179–201 mg/dL). Results: A total of 63 patients (50 men, 13 women; mean age, 64.3 years) were enrolled. Significant decreases in total cholesterol (31.3% at week 18), LDL-C (42.9% at week 18), and triglycerides (21.8% at week 18) from baseline levels were found at 6, 12, and 18 weeks of treatment ( P Conclusions: In this group of Chinese patients with CAD and hypercholesterolemia treated with atorvastatin 10 mg/d for 18 weeks, 85.2% of patients with a baseline LDL-C level of 3.4 to 4.6 mmol/L achieved the NCEP target LDL-C level of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|